Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): Study protocol of a randomized trial [ISRCTN35253449]

BMC Nephrology

Volumn 7, Issue , 2006, Pages

  Hemmelgarn, Brenda R ^a,b   Moist, Louise ^c   Pilkey, Rachel M ^d   Lok, Charmaine ^e   Dorval, Marc ^f   Tam, Paul Y W ^g   Berall, Murray J ^h   LeBlanc, Martine ⁱ   Toffelmire, Edwin B ^d   Manns, Braden J ^a,b,j   Scott Douglas, Nairne ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f Hopital Regional Geroges L Dumont   (Canada)

^g SCARBOROUGH HOSPITAL   (Canada)

^h HUMBER RIVER REGIONAL HOSPITAL   (Canada)

ⁱ MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^j INSTITUTE OF HEALTH ECONOMICS   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS FLUID; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BACTEREMIA; BLOOD FLOW; CATHETER OCCLUSION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DOSE RESPONSE; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL;

BACTEREMIA; BLOOD COAGULATION; CATHETERIZATION; COST-BENEFIT ANALYSIS; DATA COLLECTION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG COSTS; EQUIPMENT FAILURE; HEPARIN; HUMANS; LIFE TABLES; PATIENT SELECTION; RECOMBINANT PROTEINS; RENAL DIALYSIS; RESEARCH DESIGN; SAMPLE SIZE; SOLUTIONS; SURVIVAL ANALYSIS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33646582993     PISSN: 14712369     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-7-8     Document Type: Article

References (32)

1. 1999 Report, Dialysis and Renal transplantation, Canadian Organ Replacement Register. In Canadian Institute for Health Information Volume 1. Ottawa, Ontario; 1999.
2. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB: Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997, 127(4):275-280.
3. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL: Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997, 26(6):1009-1019.
4. Swartz RD, Messana JM, Boyer CJ, Lunde NM, Weitzel WF, Hartman TL: Successful use of cuffed central venous hemodialysis catheters inserted percutaneously. J Am Soc Nephrol 1994, 4(9):1719-1725.
5. Trerotola SO, Johnson MS, Harris VJ, Shah H, Ambrosius WT, McKusky MA, Kraus MA: Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology 1997, 203(2):489-495.
6. Trivedi HS, Twardowski ZJ: Use of double-lumen dialysis catheters. Loading with locked heparin. ASAIO Journal 1997, 43(6):900-903.
7. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001, 37(1 Suppl 1):S137-S181.
8. Randolph AG, Cook DJ, Gonzales CA, Andrew M: Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 1998, 113(1):165-171.
9. Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P: Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artificial Organs 1998, 22(11):945-947.
10. Stas KJ, Vanwalleghem J, De Moor B, Keuleers H: Trisodium citrate 30% vs. heparin 5% as catheter lock in the interdialytic period in twin- or double-lumen dialysis catheters for intermittent haemodialysis. Nephrol Dial Transplant 2001, 16(7):1521-1522.
11. Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y: A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. Int JArtif Organs 2001, 24(4):208-211.
12. Weijmer MC, van den Dorpel MA, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer AM, Siegert CE, Stas KJ: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005, 16(9):2769-2777.
13. Little MA, Walshe JJ: A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. Am J Kidney Dis 2002, 39(1):86-91.
14. Daeihagh P, Jordan J, Chen J, Rocco M: Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 2000, 36(1):75-79.
15. MacRae JM, Loh G, Djurdjev O, Shalansky S, Werb R, Levin A, Kiaii M: Short and Long Alteplase Dwells in Dysfunctional Hemodialysis Catheters. Hemodialysis International 2005:189-195.
16. Savader SJ, Haikal LC, Ehrman KO, Porter DJ, Oteham AC: Hemodialysis catheter-associated fibrin sheaths: treatment with a low-dose rt-PA infusion. J Vasc Interv Radiol 2000, 11(9):1131-1136.
17. Schenk P, Rosenkranz AR, Wolfl G, Horl WH, Traindl O: Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. Am J Kidney Dis 2000, 35(1):130-136.
18. Little MA, O'Riordan A, Lucey B, Farrell M, Lee M, Conlon PJ, Walshe JJ: A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters. Nephrol Dial Transplant 2001, 16(11):2194-2200.
19. Beathard GA: Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999, 10(5):1045-1049.
20. Saad TF: Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999, 34(6):1114-1124.
21. Saad TF: Central venous dialysis catheters: catheter-associated infection. Semin Dial 2001, 14(6):446-451.
22. Raad I: Intravascular-catheter-related infections. Lancet 1998, 351(9106):893-898.
23. McGee DC, Gould MK: Preventing complications of central venous catheterization. N Engl J Med 2003, 348(12):1123-1133.
24. Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF, Barker J, Allon M: Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002, 61(3):1136-1142.
25. McIntyre CW, Hulme LJ, Taal M, Fluck RJ: Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004, 66(2):801-805.
26. Saxena AK, Panhotra BR, Naguib M: Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibiotic-heparin lock. Pharmacotherapy 2002, 22(1):105-108.
27. Haire WD: Techniques in dosing for thrombolysis of occluded central venous catheters. Tech Vasc Interv Radiol 2001, 4(2):127-130.
28. Atkinson JB, Bagnall HA, Gomperts E: Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. J Parenter Enteral Nutr 1990, 14(3):310-311.
29. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER, Semba CP: Cardiovascular Thrombolytic to Open Occluded Lines-. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol 2002, 20(1):317-324.
30. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER: Investigators COOL. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001, 12(8):951-955.
31. Preventing infections associated with indwelling intravascular access devices. Can Commun Dis Rep 1997, 23(Suppl 8):i-32. i
32. Manns B, Tonelli M, Yilmaz S, Lee H, Laupland K, Klarenbach S, Radkevich V, Murphy B: Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. J Am Soc Nephrol 2005, 16(1):201-209.